Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention
Grazia R. Tundo, Diego Sbardella, Francesco Oddone, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4852-4852
Open Access | Times Cited: 19

Showing 19 citing articles:

New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers
Hind Atta, Nouran Alzahaby, Nadia Μ. Hamdy, et al.
Bioorganic Chemistry (2023) Vol. 133, pp. 106427-106427
Closed Access | Times Cited: 14
Diethyldithiocarbamate-copper complex ignites the tumor microenvironment through NKG2D-NKG2DL axis
Daciana Catalina Dumut, Marián Hajdúch, Amanda Zacharias, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy
Silvia D’Amico, Patrizia Tempora, Ombretta Melaiu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Malignancies in Patients with Celiac Disease: Diagnostic Challenges and Molecular Advances
Mariia Ivanova, Luca Bottiglieri, Elham Sajjadi, et al.
Genes (2023) Vol. 14, Iss. 2, pp. 376-376
Open Access | Times Cited: 12
The dichotomous role of immunoproteasome in cancer: Friend or foe?
Boya Chen, Haiying Zhu, Bo Yang, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 5, pp. 1976-1989
Open Access | Times Cited: 16
Novel frontiers in neuroprotective therapies in glaucoma: Molecular and clinical aspects
Alessandra Boccaccini, Dario Cavaterra, Carmela Carnevale, et al.
Molecular Aspects of Medicine (2023) Vol. 94, pp. 101225-101225
Open Access | Times Cited: 9
Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases
Priyanka S. Rana, James J. Ignatz-Hoover, James J. Driscoll
Cancers (2023) Vol. 15, Iss. 23, pp. 5632-5632
Open Access | Times Cited: 9
Differential Interactions of the Proteasome Inhibitor PI31 with Constitutive and Immuno-20S Proteasomes
Jason Wang, Abbey Kjellgren, George Demartino
Biochemistry (2024) Vol. 63, Iss. 8, pp. 1000-1015
Open Access | Times Cited: 2
Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy
Lindy Davis, Ashley Tarduno, Yong‐Chen Lu
Cancers (2021) Vol. 13, Iss. 23, pp. 6061-6061
Open Access | Times Cited: 12
Targeting immunoproteasome in neurodegeneration: A glance to the future
Grazia R. Tundo, Paolo Cascio, Danilo Milardi, et al.
Pharmacology & Therapeutics (2022) Vol. 241, pp. 108329-108329
Closed Access | Times Cited: 8
The Immunopeptidomics Ontology (ImPO)
Daniel Faria, Patrícia Eugénio, Marta Contreiras Silva, et al.
Database (2024) Vol. 2024
Open Access | Times Cited: 1
Myelin Basic Protein Fragmentation by Engineered Human Proteasomes with Different Catalytic Phenotypes Revealed Direct Peptide Ligands of MS-Associated and Protective HLA Class I Molecules
George A. Saratov, Vasiliy I. Vladimirov, Alexey L. Novoselov, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2091-2091
Open Access | Times Cited: 3
The Insulin-Degrading Enzyme from Structure to Allosteric Modulation: New Perspectives for Drug Design
Grazia R. Tundo, Giuseppe Grasso, Marco Persico, et al.
Biomolecules (2023) Vol. 13, Iss. 10, pp. 1492-1492
Open Access | Times Cited: 3
Prognostic association of immunoproteasome expression in solid tumours is governed by the immediate immune environment
Rahul Kumar, Bhavya Dhaka, Sarthak Sahoo, et al.
Molecular Oncology (2023) Vol. 17, Iss. 6, pp. 1041-1059
Open Access | Times Cited: 2
Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma
Tongji Xie, Guangyu Fan, Liling Huang, et al.
Epigenomics (2022) Vol. 14, Iss. 22, pp. 1427-1448
Closed Access | Times Cited: 2
Nilabh Shastri – Towards understanding classical and non-classical MHC-I antigen processing and presentation
Benedikt M. Kessler
Cellular Immunology (2022) Vol. 382, pp. 104638-104638
Open Access | Times Cited: 1
Cofilin1 Is a Poorer Prognostic Biomarker and potential Immunotherapy in Systematic Pan-Cancer
Jin Yang, Cheng-Jie Qiu, Shan Zhong, et al.
Research Square (Research Square) (2022)
Open Access
Modulation of the 20S Proteasome Activity by Porphyrin Derivatives Is Steered through Their Charge Distribution
Marco Persico, Anna Maria Santoro, Alessandro D’Urso, et al.
Biomolecules (2022) Vol. 12, Iss. 6, pp. 741-741
Open Access
Prognostic association of immunoproteasome expression in solid tumours is governed by the immediate immune environment
Rahul Kumar, Bhavya Dhaka, Sarthak Sahoo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top